BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as BB-10901, can block tumor growth in different ways.
Some block the ability of tumor cells to grow and spread. Others find tumor cells and help
kill them or carry tumor-killing substances to them.
PURPOSE: This phase I trial is studying the side effects and best dose of BB-10901 in
treating patients with relapsed or refractory solid tumors.